alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Summary – ORAUT-PROC-0002, Rev. 01 1 SC&A – January 20, 2011

Overview of

USE OF INTEGRATED MODULES FOR BIOASSAY ANALYSIS (IMBA)

(ORAUT-PROC-0002, Rev. 01)

Workers at Department of Energy and Atomic Weapons Employer facilities have the potential to 

be exposed to an amount of radiation which must be estimated for claimants. An important tool 

to determine radiation doses to internal tissue and organs is the computer code or specialized 

computer program known as IMBA (Integrated Modules for Bioassay Analysis). This subject 

procedure, Use of Integrated Modules for Bioassay Analysis (IMBA) (ORAUT-PROC-0002), 

provides guidance in running the code. This procedure, with references to several other 

documents, describes only the mechanics of running IMBA software, and does not provide 

guidance on performing a dose estimate. 

SUMMARY OF FINDINGS RESULTING FROM THE TECHNICAL REVIEW

Review of the procedure by the technical contractor for the Advisory Board on Radiation and 

Worker Health (the Board) produced the three findings summarized below: 

Finding #1: The procedure lacks clear descriptions for the location of various functional buttons 

related to the IMBA program that are shown on the computer screen. 

Finding #2: The procedure lacks sufficient guidance on evaluating results of bioassay 

calculations.

Finding #3: The procedure provides users with insufficient guidance in cases where 

professional judgment is required. 

RESOLUTION OF FINDINGS

In response to the findings identified above, the National Institute for Occupational Safety and 

Health (NIOSH) stated that this procedure is intended as an introduction to the use of IMBA and 

provides sufficient detail so that a novice user can quickly and easily operate the computer code. 

After only a little experience, the user has no need for the additional specificity called for by the

comments. In addition, NIOSH provides IMBA users with training in the use of the code. 

The NIOSH explanation was accepted; all issues were resolved to the satisfaction of the Board.
**EXHIBIT 32.2**

 

**CERTIFICATIONPURSUANT TO**

**18 U.S.C. SECTION 1350,**

**AS ADOPTEDPURSUANT TO**

**SECTION 906OF THE SARBANES-OXLEY ACT OF 2002**

 

In connection with theQuarterly Report of Adelphia Recovery Trust (the “Trust”) on Form 10-Q forthe period ended September 30, 2009 as filed with the Securities andExchange Commission on the date hereof (the “Report”), I, Jeffrey A. Brodsky, amember of Quest Turnaround Advisors, LLC, Trust Administrator of the Trust,certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of theSarbanes-Oxley Act of 2002, that to the best of my knowledge:

 

1. The Report fully complies with the requirements ofsection 13(a) or 15(d) of the Securities Exchange Act of 1934;and

 

2. The information contained in the Report fairly presents, in allmaterial respects, the financial condition and results of operations of theTrust.

 

 

By:  Quest Turnaround Advisors, LLC

as Trust Administrator ofthe Adelphia Recovery Trust

 
| /s/ Jeffrey A. Brodsky       |   |
|------------------------------|--------|
| Jeffrey A. Brodsky           |
| Member                       |
|                         |
|                         |
| Date: November 6,  2009 |

 

----
Exhibit
      32.1





I,
      Dr.
      David Dalton, Chief Executive Officer of Univec, Inc., certify,
      pursuant


to
      18
      U.S.C. 1350, as enacted by 906 of the Sarbanes-Oxley Act of 2002,


that:





(1)
      the
      Annual Report on Form 10-KSB for the annual period ended December
      31,


2004
      (the
      "Periodic Report") which this statement accompanies fully complies


with
      the
      requirements of Section 13(a) or 15(d) of the Securities Exchange
      Act


of
      1934;
      and





(2)
      the
      information contained in the Periodic Report fairly presents, in
      all


material
      respects, the financial condition and results of operations of
      Univec,


Inc.








Dated:
      September 15, 2005





By:
      /s/ David Dalton


Dr.
      David
      Dalton, Chief Executive Officer
Enc.

ADVISORY BOARD ON RADIATION AND WORKER HEALTH

4676 Columbia Parkway, MS: C-46 

Cincinnati, Ohio 45226

(513) 533-6825

CHAIRMAN

James M. Melius, M.D., Dr. PH.

 Albany, New York

MEMBERS

Henry Anderson, M.D.

 Madison, Wisconsin

Josie Beach

 Kennewick, Washington 

Bradley P. Clawson

 Rexburg, Idaho

R. William Field, Ph.D. 

 Iowa City, Iowa

Michael H. Gibson

 Franklin, Ohio

Mark A. Griffon

 Salem, New Hampshire

Richard Lemen, Ph.D.

 Canton, Georgia

James E. Lockey, M.D.

 Cincinnati, Ohio

Wanda I. Munn

 Richland, Washington

John W. Poston, Sr., Ph.D.

 College Station, Texas

Robert W. Presley

 Seymour, Tennessee

David B. Richardson, Ph.D.

Chapel Hill, North Carolina

Genevieve S. Roessler, Ph.D.

 Elysian, Minnesota

Phillip Schofield

 Bosque Farm, New Mexico

Paul L. Ziemer, Ph.D.

 Lafayette, Indiana

STAFF

EXECUTIVE SECRETARY

Theodore M. Katz, MPA

 Atlanta, Georgia

COMMITTEE MANAGEMENT 

Zaida Burgos

 Atlanta, Georgia

March 28, 2011

The Honorable Kathleen Sebelius

Secretary 

Department of Health and Human Services

200 Independence Avenue, S.W.

Washington, D.C. 20201

Dear Madam Secretary:

The Advisory Board on Radiation and Worker Health (The Board) has evaluated 

Special Exposure Cohort (SEC) Petition 00043 concerning employees who 

worked at the Chapman Valve Manufacturing Company in Indian Orchard, 

Massachusetts, under the statutory requirements established by the Energy 

Employees Occupational Illness Compensation Program Act of 2000 

(EEOICPA) and incorporated into 42 CFR Sec. 83.13. The National Institute for 

Occupational Safety and Health (NIOSH) has recommended that individual 

dose reconstructions are feasible for workers at the Chapman Valve 

Manufacturing Company (i.e., Building 23 and the Dean Street facility) in Indian 

Orchard, Massachusetts, from January 1, 1948 through December 31, 1949, 

and from January 1, 1991 through December 31, 1993. 

NIOSH found that it has access to adequate exposure monitoring and other 

information necessary to do individual dose reconstructions with sufficient 

accuracy for members of this group, and therefore a class covering this group 

should not be added to the SEC. The Board concurs with this determination.

Enclosed is supporting documentation from the February 23-25, 2011 Board 

meeting held in Augusta, Georgia, and earlier meetings where this potential 

class for the SEC was discussed. If any of these items are unavailable at this 

time, they will follow shortly. 

 Sincerely,

 [Signature on file]

James M. Melius, M.D., Dr. PH

Chairman, ABRWH

Enclosure
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 21-1167

FLORDELIZA A. HAWKINS,

 Plaintiff - Appellant,

v.

COURT OF COMMON PLEAS OF ANDERSON SOUTH CAROLINA; 

SUNTRUST BANK; JOSEPH PARTAIN,

 Defendants - Appellees.

Appeal from the United States District Court for the District of South Carolina, at 

Anderson. Donald C. Coggins, Jr., District Judge. (8:20-cv-03432-DCC)

Submitted: August 24, 2021 Decided: August 26, 2021

Before NIEMEYER and HARRIS, Circuit Judges, and SHEDD, Senior Circuit Judge.

Affirmed by unpublished per curiam opinion.

Flordeliza A. Hawkins, Appellant Pro Se.

Unpublished opinions are not binding precedent in this circuit.
2

PER CURIAM:

Flordeliza A. Hawkins appeals the district court’s order accepting the 

recommendation of the magistrate judge and denying relief on Hawkins’ 42 U.S.C. § 1983 

complaint. We have reviewed the record and find no reversible error. Accordingly, we 

affirm the district court’s order. We dispense with oral argument because the facts and 

legal contentions are adequately presented in the materials before this court and argument 

would not aid the decisional process.

AFFIRMED
RICH
PHARMACUETICALS, INC.


2013
EQUITY INCENTIVE PLAN AMENDMENT NO. 3


 


December 15, 2015


 


WHEREAS,
Rich Pharmaceuticals, Inc., a Nevada corporation (the "Corporation"), has adopted the 2013 Equity Incentive Plan
(the “2013 Plan”) and reserved 60,004,800 shares of the Corporation's common stock (the "Shares")
under the 2013 Plan;


WHEREAS,
on October 6, 2014, pursuant to the terms of the Plan, the Board of Directors approved an amendment to the 2013 Plan to increase
the amount of shares reserved for issuance to a total of 90,004,800 Shares;


WHEREAS,
on April 6, 2015, pursuant to the terms of the Plan, the Board of Directors approved an amendment to the 2013 Plan to increase
the amount of shares reserved for issuance to a total of 390,004,800 shares;


NOW,
THEREFORE, the 2013 Plan is hereby amended to provide that the total number of Shares reserved for issuance under the 2013 Plan
is 1,200,000,000.


 





By:
/s/ Ben Chang


Ben
Chang, CEO
**Exhibit
      31.2**





**Rule
      13a-14(a) / 15d-14(a) Certification of Chief Financial
      Officer**





I,
      William Danis,
      certify that:





1.
      I have reviewed
      this report on Form 10-K of Med-Emerg International Inc.;





2.
      Based on my
      knowledge, this report does not contain any untrue statement of a material
      fact
      or omit to state a material fact necessary to make the statements made, in
      light
      of the circumstances under which such statements were made, not misleading
      with
      respect to the period covered by this report;





3.
      Based on my
      knowledge, the revised consolidated financial statements, and other financial
      information included in this report, fairly present in all material respects
      the
      financial condition, results of operations and cash flows of the registrant
      as
      of, and for, the periods presented in this report;





4.
      The registrant's
      other certifying officer and I are responsible for establishing and maintaining
      disclosure controls and procedures (as defined in Exchange Act Rules 13a-14
      and
      15d-14) for the registrant and we have:





a)
      designed such
      disclosure controls and procedures to ensure that material information relating
      to the registrant, including its consolidated subsidiaries, is made known to
      us
      by others within those entities, particularly during the period in which this
      report is being prepared;





b)
      evaluated the
      effectiveness of the registrant's disclosure controls and procedures and
      presented in this report our conclusions about the effectiveness of the
      disclosure controls and procedures, as of the end of the period covered by
      this
      report based on such evaluation; and





c)
      disclosed in
      this report any change in the registrant’s internal control over financial
      reporting that occurred during the registrant’s fiscal year that has materially
      affected, or is reasonably likely to materially affect, the registrant’s
      internal control over financial reporting.





5.
      The registrant's
      other certifying officer and I have disclosed, based on our most recent
      evaluation of internal control over financial reporting, to the registrant's
      auditors and the audit committee of the registrant's board of directors (or
      persons performing the equivalent functions):





a)
      all significant
      deficiencies and material weaknesses in the design or operation of internal
      control over financial reporting which are reasonably likely to adversely affect
      the registrant’s ability to record, process, summarize and report financial
      information; and





b)
      any fraud,
      whether or not material, that involves management or other employees who have
      a
      significant role in the registrant's internal control over financial
      reporting.





Date: November
                30, 2005/s/
              William
              DanisWilliam
                DanisChief
                Financial Officer
Subj: DTRA's NTPR Technical Report Publication Plans 

VBDR 

DTRA Draft Target DTRA 

Release Feedback Publish Corporate 

Date Date Date Author Title 

"Screening Doses for Induction of Cancers Calculated with 

Feb-06 Apr-06 May-06 Senes Interactive Radioepidemiological Program (IREP)" 

"Bounding Analysis of Effects of Fractionation of Radionuclides in 

Mar-06 May-06 Jun-06 Senes Fallout on Estimation of Doses to Atomic Veterans" 

Revision of "FIIDOS - A Computer Code for the Computation of 

Apr-06 Jun-06 Jul-06 SAIC Fallout Inhalation and Ingestion Dose to Organs" 

"Evaluation of Inhalation Doses in High-Resuspension Scenarios at 

May-06 Jul-06 Aug-06 Senes Nevada Test Site" 

"Special Study: Exposures to Old Fallout Fields for Desert Rock 

Jun-06 Aug-06 Sep-06 SAIC Trainees at Nevada Test Site through 1955" 

Jul-06 Sep-06 Oct-06 Senes "Skin Doses From Dermal Contamination" 

"Considerations on Estimating Upper Bounds of Neutron Dose 

Aug-06 Oct-06 Nov-06 Senes Equivalents to Atomic Veterans" 

Note: SAIC has offered to assist DTRA in review of selected SENES publications
Exhibit 32.1
 
 
 CERTIFICATE PURSUANT TO
 18 U.S.C. SECTION 1350
 AS ADOPTED PURSUANT TO
 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
 
 In connection with the Quarterly Report (the “Report”) on the Form 10-Q of Sweetwater Resources, Inc. (the “Company”) for the nine months ended December 31, 2010, as filed with the Securities and Exchange Commission on the date hereof, I, Jose Madappilly, Chief Executive Officer, President and Director, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:
 
 1. The Quarterly Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities and Exchange Act of 1934, as amended; and
 
 2. The information contained in this Quarterly Report fairly presents, in all material respects, the financial condition and results of operation of the Company.
 
 Dated:  February 1, 2011
 
 
 JOSE MADAPPILLY
 Jose Madappilly
 Chief Executive Officer,
 President and Director
 
 
 -1-
## NUMBER S 13

- 1 4

- 00 680

- CR

COURT OF APPEALS

THIRTEENTH DISTRICT OF TEXAS

CORPUS CHRISTI

- EDINBURG

THE STATE OF TEXAS , Appellant,

v.
ISRAEL RAMIREZ , Appellee.

On appeal from the 94th District Court of Nueces County, Texas.



## ORDER ABATING APPEAL

Before Justice s Garza , Benavides, and Perkes

Order Per Curiam
The State perfected an appeal from an order granting a motion to suppress entered
by the 94th District Court of Nueces County, Texas, in cause number 13CR 2209

- C . The

State has filed a motion to abate and remand to the trial court for findings of fact and

conclusions of law.2

On November 3 , 201 4 , the trial court issued an order granting a motion to
suppress. On November 24 , 201 4 , the State filed a timely request for findings of fact
and conclusions of law. The trial court has not made its findings of fact and conclusions
of law in support of it s decision to grant the appellee ’ s motion to suppress.
Upon the request of the losing party on a motion to suppress evidence, the trial
court must make findings of fact and conclusions of law adequate to provide an appellate

court with a basis to which to review the trial court ’ s application of the law to the facts.

State v. Cullen , 195 S.W.3d 696, 699 (Tex. Crim. App. 2006). If the trial court does not
enter the findings of fact and conclusions of law within twenty days from its ruling on the

motion to s uppress, the intermediate appellate court must exercise its authority under
Texas Rule of Appellate Procedure 44.4, and remand the case to the trial court and order
the trial court to enter findings of fact and conclusions of law. T EX

. R. A PP

. P ROC

. 44.4;

Cullen , 195 S.W.3d at 698

- 700.
The Court, having considered the documents on file and the State ’ s motion, is of
the opinion that the motion should be granted. Accordingly, we GRANT counsel ’ s motion
to abate the present appeal. See T EX

. R. A PP

. P. 44 .4. Accordingly, this appeal is

ABATED and the cause REMANDED to the trial court.
Upon remand, the trial court is instructed to make and file findings of fact and

conclusions of law in support of its order granting the motion to suppress in this cause,
as requested by the State in its motion filed November 24, 2014. See Cullen

. The trial

court shall cause its findings of fact and conclusions of law to be included in a
supplemental clerk's record filed with the Court within thirty days from the date of this3

order. Should the trial court require more time to comply with this order, it shall request
an extension prior to the expiration of this deadline.

It is so ORDERED.

PER CURIAM
Do not publish. T EX

. R. A PP

. P. 47.2(b).

Delivered and filed the 12 th day of Ma rch , 201 5

.
```

[Congressional Bills 106th Congress]
[From the U.S. Government Publishing Office]
[S. 1505 Introduced in Senate (IS)]

106th CONGRESS
  1st Session
                                S. 1505

  To amend the Small Business Act to extend the authorization for the 
                      drug-free workplace program.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                             August 5, 1999

 Mr. Coverdell (for himself, Mr. Kyl, and Mr. Abraham) introduced the 
 following bill; which was read twice and referred to the Committee on 
                             Small Business

_______________________________________________________________________

                                 A BILL

 
  To amend the Small Business Act to extend the authorization for the 
                      drug-free workplace program.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Drug-Free Workplace Fair 
Demonstration Act''.

SEC. 2. DRUG-FREE WORKPLACE PROGRAM EXTENSION.

    Section 27(g)(1) of the Small Business Act (15 U.S.C. 654(g)(1)) is 
amended by striking ``$10,000,000 for fiscal years 1999 and 2000'' and 
inserting ``$20,000,000 for fiscal years 1999 through 2002''.
                                 <all>
```
# Dziennik Urzędowy L 124/2016

| | ISSN 1977-0766 |
| --- | --- |
| Dziennik Urzędowy
  Unii Europejskiej | L 124 |
| | |
| Wydanie polskie | Legislacja | Rocznik 5913 maja 2016 |

ISSN 1977-0766

Dziennik Urzędowy

Unii Europejskiej

L 124

Wydanie polskie

Legislacja

Rocznik 5913 maja 2016

---

| Spis treści | | II   Akty o charakterze nieustawodawczym | Strona |
| --- | --- | --- | --- |
| | | POROZUMIENIA MIĘDZYINSTYTUCJONALNE |
| | * | Oświadczenie Parlamentu Europejskiego i Komisji z okazji przyjęcia porozumienia międzyinstytucjonalnego w sprawie lepszego stanowienia prawa z dnia 13 kwietnia 2016 r. | 1 |

Spis treści

II   Akty o charakterze nieustawodawczym

Strona

POROZUMIENIA MIĘDZYINSTYTUCJONALNE

*

Oświadczenie Parlamentu Europejskiego i Komisji z okazji przyjęcia porozumienia międzyinstytucjonalnego w sprawie lepszego stanowienia prawa z dnia 13 kwietnia 2016 r.

1

| PL | Akty, których tytuły wydrukowano zwykłą czcionką, odnoszą się do bieżącego zarządzania sprawami rolnictwa i generalnie zachowują ważność przez określony czas.
  Tytuły wszystkich innych aktów poprzedza gwiazdka, a drukuje się je czcionką pogrubioną. |
| --- | --- |

PL

Akty, których tytuły wydrukowano zwykłą czcionką, odnoszą się do bieżącego zarządzania sprawami rolnictwa i generalnie zachowują ważność przez określony czas.

Tytuły wszystkich innych aktów poprzedza gwiazdka, a drukuje się je czcionką pogrubioną.

---

II Akty o charakterze nieustawodawczym

POROZUMIENIA MIĘDZYINSTYTUCJONALNE

| 13.5.2016 | PL | Dziennik Urzędowy Unii Europejskiej | L 124/1 |
| --- | --- | --- | --- |

13.5.2016

PL

Dziennik Urzędowy Unii Europejskiej

L 124/1

---

OŚWIADCZENIE PARLAMENTU EUROPEJSKIEGO I KOMISJI Z OKAZJI PRZYJĘCIA POROZUMIENIA MIĘDZYINSTYTUCJONALNEGO W SPRAWIE LEPSZEGO STANOWIENIA PRAWA Z DNIA 13 KWIETNIA 2016 R.

Parlament Europejski i Komisja są zdania, że przedmiotowe Porozumienie (1) odzwierciedla równowagę między Parlamentem Europejskim, Radą i Komisją oraz przysługujące tym instytucjom kompetencje zgodnie z Traktatami.

1

Pozostaje ono bez uszczerbku dla Porozumienia ramowego z dnia 20 października 2010 r. w sprawie stosunków między Parlamentem Europejskim i Komisją Europejską (2).

2

---

(1)  
  Dz.U. L 123 z 12.5.2016, s. 1.

1

(2)  
  Dz.U. L 304 z 20.11.2010, s. 47.

2

---
<PAGE>

                              Sonic Foundry, Inc.
                           Annual Report on Form 10-K
                     For the Year Ended September 30, 2002


 EXHIBIT 99.2

          CERTIFICATION OF PERIODIC REPORT

     Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C.
Section 1350, the undersigned officer of Sonic Foundry, Inc. (the "Company"),
hereby certifies that:

     (1) the Company's Annual Report on Form 10-K for the period ended September
30, 2002 (the "Report") fully complies with the requirements of Section 13(a) or
15(d), as applicable, of the Securities Exchange Act of 1934; and

     (2) the information contained in the Report fairly presents, in all
material respects, the financial condition and results of operations of the
Company.

Dated:  January 24, 2003


                                  /s/ Kenneth A. Minor
                                  ------------------------------
                                  Name:  Kenneth A. Minor
                                  Title: Chief Financial Officer
<PAGE>
                                  EXHIBIT 21.1
                 LIST OF SUBSIDIARIES OF ATRIUM COMPANIES, INC.
 
Atrium Door and Window Company of the Northeast, a Connecticut corporation (the
merged companies formerly named Vinyl Building Specialties of Connecticut, Inc.
and Bishop Manufacturing Company, Incorporated) (direct subsidiary)
 
Atrium Door and Window Company of New England, a Connecticut corporation
(formerly Bishop Manufacturing Company of New England, Inc.) (direct subsidiary
of Atrium Door and Window Company of the Northeast, indirect subsidiary of
Atrium Companies, Inc.)
 
Atrium Door and Window Company of New York, a Connecticut corporation (formerly
Bishop Manufacturing Company of New York, Inc.) (direct subsidiary)
 
Atrium Door and Window Company - West Coast, a Texas corporation (formerly H-R
Window Supply, Inc.) (direct subsidiary)
 
Atrium Door and Window Company of Arizona, a Delaware corporation (direct
subsidiary)
 
Wing Industries Holdings, Inc., a Delaware corporation (direct subsidiary)
 
Wing Industries, Inc., a Texas corporation (direct subsidiary of Wing Industries
Holdings, Inc., indirect subsidiary of Atrium Companies, Inc.)
 
Door Holdings, Inc., a Delaware corporation (direct subsidiary)
 
R.G. Darby Company, Inc., a Delaware corporation (direct subsidiary of Door
Holdings, Inc., indirect subsidiary of Atrium Companies, Inc.)
 
Total Trim, Inc., a Delaware corporation, (direct subsidiary of Door Holdings,
Inc., indirect subsidiary of Atrium Companies, Inc.)